PMID- 19605944
OWN - NLM
STAT- MEDLINE
DCOM- 20091130
LR  - 20221207
IS  - 1734-1140 (Print)
IS  - 1734-1140 (Linking)
VI  - 61
IP  - 3
DP  - 2009 May-Jun
TI  - Effect of fluoxetine on tolerance to the analgesic effect of morphine in mice 
      with skin cancer.
PG  - 453-8
AB  - Adjuvant drugs that attenuate or inhibit the development of tolerance to morphine 
      may lead to improved management of pain in chronic diseases such as cancer. The 
      aim of this study was to investigate effect of fluoxetine, a specific 5-HT 
      (5-hydroxytryptamine, serotonin) reuptake inhibitor, on tolerance induced to the 
      analgesic effect of morphine in mice with skin cancer. The study was carried out 
      on female Swiss albino mice. For skin tumorigensis, mice were initiated with a 
      single dose of 7,12-dimethylbenz(a)anthracene (DMBA) and promoted by multiple 
      doses of croton oil. Tolerance to morphine analgesia was induced by daily 
      subcutaneous (sc) injections of morphine (5 mg/kg for 30 days) and assayed using 
      the hot plate method. Results obtained from this study showed that pain 
      thresholds in mice with skin cancer were significantly lower. Tolerance to the 
      analgesic effect of morphine (5 mg/kg, sc) appeared at day 15, whereas in normal 
      and skin tumor bearing mice co-treated daily with morphine (5 mg/kg, sc) and 
      three different intraperitoneal (ip) doses of fluoxetine (0.16, 0.32 and 0.64 
      mg/kg) tolerance was observed at days 20, 25 and 30, respectively. In conclusion, 
      our data indicate that concurrent use of morphine with fluoxetine may produce 
      good cancer pain control and attenuate the development of tolerance.
FAU - Nayebi, Alireza Mohajjel
AU  - Nayebi AM
AD  - Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz 
      51664, Iran. nayebia@yahoo.com
FAU - Rezazadeh, Hassan
AU  - Rezazadeh H
FAU - Parsa, Yousef
AU  - Parsa Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Pharmacol Rep
JT  - Pharmacological reports : PR
JID - 101234999
RN  - 0 (Analgesics, Opioid)
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 01K63SUP8D (Fluoxetine)
RN  - 76I7G6D29C (Morphine)
SB  - IM
MH  - Analgesics, Opioid/pharmacology/therapeutic use
MH  - Animals
MH  - *Drug Interactions
MH  - *Drug Tolerance
MH  - Female
MH  - Fluoxetine/*pharmacology/therapeutic use
MH  - Mice
MH  - Morphine/*pharmacology/therapeutic use
MH  - Pain/*drug therapy
MH  - Pain Threshold/drug effects
MH  - Selective Serotonin Reuptake Inhibitors/pharmacology/therapeutic use
MH  - Skin Neoplasms/chemically induced/*drug therapy
EDAT- 2009/07/17 09:00
MHDA- 2009/12/16 06:00
CRDT- 2009/07/17 09:00
PHST- 2008/08/09 00:00 [received]
PHST- 2009/04/20 00:00 [revised]
PHST- 2009/07/17 09:00 [entrez]
PHST- 2009/07/17 09:00 [pubmed]
PHST- 2009/12/16 06:00 [medline]
AID - S1734-1140(09)70086-6 [pii]
AID - 10.1016/s1734-1140(09)70086-6 [doi]
PST - ppublish
SO  - Pharmacol Rep. 2009 May-Jun;61(3):453-8. doi: 10.1016/s1734-1140(09)70086-6.